Company: CSDX
Filing Date: 2025-10-31
Form Type: 8-K
Source: 0001214659-25-015660
Chunk: 0

Company: CS DIAGNOSTICS CORP.
Filing Date: 2025-10-31
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events

On October 30, 2025, CS Diagnostics Corp. (the “ Company”
or “ CSDX”) completed the conversion of all outstanding shares of its Series B Preferred Stock (the “ Preferred B Shares”)
held by its affiliate companies, CS Interpharm General Trading Co. LLC (“ CS Interpharm”) and CS Diagnostics Pharma GmbH (“ CS
Diagnostics Pharma”), into shares of the Company’s Common Stock, par value $0.00001 per share (the “ Common Shares”).

The conversion was affected pursuant to the terms of the Certificate
of Designation governing the Preferred B Shares and resulted in the issuance of an aggregate 112,652,000 Common Shares. The conversion
aligns the capital structures of the Company and its affiliates in preparation for consolidated financial reporting for the fiscal year
ending December 31, 2025.

The Common Shares issued upon conversion were not registered under
the Securities Act of 1933, as amended (the “ Securities Act”), and were issued in reliance on the exemption from registration
provided by Section 3(a)(9) thereof, as the exchange was made exclusively with existing security holders, no commission or other remuneration
was paid or given directly or indirectly for soliciting such exchange, and the affiliates are not issuers, underwriters, or dealers. Alternatively,
to the extent applicable, the transaction also qualifies for exemption under Section 4(a)(2) as a transaction not involving a public offering.

This strategic conversion simplifies the Company’s equity capitalization,
enhances transparency, and strengthens alignment among CSDX and its affiliated entities. Following the conversion, the affiliates now
hold their ownership interests directly through Common Shares, fostering greater alignment with all shareholders and supporting long-term
value creation and financial consolidation. Notably, the consolidation will integrate the income and revenue streams from CS Interpharm
and CS Diagnostics Pharma directly into CSDX's financial statements, providing a more comprehensive view of the group's operational performance
and growth potential.

As affiliates of the Company, CS Interpharm and CS Diagnostics Pharma
remain subject to the resale limitations of Rule 144 under the Securities Act, including filing, volume, manner-of-sale, and current-public-information
requirements designed to promote orderly trading activity and investor protection.

On October 31, 2025, the Company issued a press release announcing
completion of the conversion. A copy of that press release is furnished as Exhibit 99.1 to